Lexaria Bioscience Corp. LEXX
3.28
(0.09)
(2.67%)
as of 25 Sep
- Market cap
- $7.1M
- P/E
- 0.0×
Follow LEXX
Growth Flags
show if company had growth for consecutive years
| May '26 | Feb '26 | Nov '25 | Aug '25 | Older periods | |
|---|---|---|---|---|---|
| (162.60%) | (146.94%) | (155.10%) | (231.96%) |
+8 more TTM periods Free account |
|
| (134.20%) | (125.68%) | (136.24%) | (182.50%) | ||
ROIC |
(662.56%) | (628.69%) | (6,795.20%) | (1,168.81%) | |
Return on Tangible Assets |
(197.72%) | (164.35%) | (261.80%) | (540.28%) | |
Average Days of Receivables |
0.00 | 28.28 | 0.00 | 190.49 | |
Free Cash Flow per Share |
(4.55) | (5.81) | (6.15) | (8.79) | |
Free Cash Flow |
(7.53) | (9.47) | (8.78) | (10.55) | |
Capital Expenditures |
(0.10) | (0.09) | (0.07) | (0.10) | |
Piotroski F-Score |
— | 2.00 | — | 3.00 | |
| Other line items | |||||
Cash ROIC |
(93.27%) | (81.66%) | (97.32%) | (228.66%) | |
Accounts Receivable Turnover |
0.00 | 2.90 | 0.00 | 2.70 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 1,060.20% | 0.00% | 1,167.12% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 753.91% | 0.00% | 615.55% | |
Share Based Compensation of Revenue |
0.00% | 137.03% | 0.00% | 121.76% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.96 | 0.98 | 0.81 | 0.88 | |
Depreciation/Fixed assets |
0.33 | 0.36 | 0.33 | 0.38 | |
Capex/Depreciation |
(1.33) | (1.08) | (0.94) | (1.14) | |
Revenue per Share |
0.00 | 0.33 | 0.00 | 0.59 | |
Operating CF per Share |
(4.49) | (5.75) | (6.11) | (8.70) | |
Capex per Share |
(0.06) | (0.06) | (0.05) | (0.08) | |
Capex to Sales |
0.00 | 0.18 | 0.00 | 0.14 | |
Net Profit Margin |
0.00% | (1,758.28%) | 0.00% | (1,686.05%) |
Columns are period end dates